BeMob Tracking Pixel
No Result
View All Result
No Result
View All Result
No Result
View All Result

You might also like

Disseminated on behalf of Rocket Doctor AI Inc. 

The AI Healthcare Reset: A Disrupting Medical Platform Opportunity No One Sees Coming In A Trillion Dollar Setting

The global healthcare system is breaking and no one inside it is surprised.

 

Costs are exploding. Access is collapsing. Doctors are burning out at historic rates.

 

What if you knew first, before the masses, about a quiet platform that is re-engineering how healthcare works today?   

Patients are waiting weeks or sometimes months for care that should take minutes.

 

Governments are scrambling. Insurers are rationing. Hospitals are overloaded.

 

And yet, demand keeps rising.1

 

An aging population. Chronic disease. Mental health crises. Post-pandemic care backlogs. The rise of AI-driven diagnostics. The expectation of instant, on-demand service.

 

Healthcare is no longer a properly functioning system; it’s a pressure cooker.

 

This is not a future problem. It’s happening now.2

 

And whenever a system becomes too large, too slow, and too expensive to fix from within, infrastructure gets replaced.

 

That’s exactly what happened to banking, retail, media, transportation, and communications.

 

And now, healthcare has reached that same inflection point.3

 

But here’s the part most investors still don’t understand:

  • The healthcare revolution will not be led by hospitals.
  • It will not be led by governments.
  • And it will not be led by “apps.”

It will be led by AI-powered medical infrastructure, built quietly, validated by doctors, integrated with payers, and scaled before the public realizes what’s happening.

 

That’s where this story begins: Enter Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) the quiet platform re-engineering how healthcare actually works.

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is building a full-stack, AI-powered healthcare platform that spans the entire patient journey from intake through triage, consultation, documentation, follow-up, and ongoing care. 

 

All powered by a single AI brain deployed across multiple touchpoints.

 

But the real secret weapon isn’t the interface.

 

It’s the intelligence layer behind it. 

 

More on that further below, but for now let’s dive further into AI applications in healthcare. 

The Great Misunderstanding: Why MOST AI Healthcare Bets Will Fail

Right now, investors are chasing “AI in healthcare” the same way they once chased “apps in finance” or “dot-coms in retail.”4

 

Everyone sees the buzz.

 

Few understand the bottlenecks.

 

Most AI healthcare companies fall into one of three traps: 

  • They build flashy tools with no real clinical validation. 
  • They ignore regulation, reimbursement, and payer systems. 
  • And they underestimate how hard real adoption actually is.

Healthcare is not tech. It is not software. It is not consumer SaaS. Healthcare is a regulated, reimbursed, permission-based system where distribution, trust and accuracy matters more than innovation.5

 

That’s why 99% of AI health startups will never scale.

 

Most “AI diagnosis” apps will never be reimbursed.

 

And most platforms will die long before reaching profitability.

 

The winners will not be the loudest. They will be the most embedded.

 

And that’s why Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is taking a fundamentally different approach.

This Is Not an "AI App" Story - This is an Execution and Infrastructure Story

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is not trying to “disrupt healthcare” with hype.

 

It’s doing something far more dangerous, and far more valuable.

 

It’s quietly building AI-powered medical infrastructure that is designed by doctors, for doctors.

 

Infrastructure that works inside the healthcare system, not around it. 

 

Infrastructure that has the potential to integrate with payers, EMRs, and compliance frameworks. 

 

Infrastructure that is designed to scale through execution, not marketing. And infrastructure that becomes harder to replace the bigger it gets.

 

This is not a consumer app.

 

This is not a one-trick AI model.

 

This is not a speculative moonshot.

 

This is a platform being installed underneath healthcare delivery.

 

And once infrastructure is embedded, it doesn’t get removed, it gets expanded.

Why is AI in Healthcare No Longer Optional

Artificial intelligence is not entering healthcare because it’s trendy.

 

It’s entering because the system can no longer function without it.

 

Consider the reality. More than $100 billion is lost annually to misdiagnosis in the United States alone.6 Millions of Americans are affected by diagnostic errors every year.

 

Physicians are overwhelmed with administrative tasks, spending 40% of their time on administrative work rather than patient care.7

 

Nurses are stretched beyond capacity. Triage is inefficient and inconsistent. Patient intake is slow and error-prone. Follow-ups fall through the cracks.8

 

Costs are rising faster than GDP. And access is shrinking, not improving.9

 

Now layer in AI. Suddenly intake becomes automated. Triage becomes intelligent.

 

Documentation becomes instant. Follow-ups become systematic. Doctors focus on care, not paperwork. And systems scale without hiring armies of staff.10

 

AI done right doesn’t replace doctors.

 

It empowers and amplifies them.

 

And the platforms that enable this amplification will own the future of care delivery.

THE GLOBAL LIBRARY OF MEDICINE (GLM): THE MOAT MOST INVESTORS MISS

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has built a complete AI-powered healthcare platform covering the entire patient journey, from intake to ongoing care, powered by one unified AI brain across all touchpoints.11

 

At the core of Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is a proprietary platform which no competitor can easily replicate.

 

The real advantage, the intelligence layer behind it: The Global Library of Medicine (GLM).

 

This is not a generic large language model.

 

This is not scraped internet data.

 

And, this is not an experimental AI chatbot.

 

GLM is a clinically validated, expert-reviewed medical intelligence engine built over 10 years from over 25,000 clinician hours of expert input, more than 10,000 expert medical reviews, coverage of 1,000+ diseases and over 17,000 symptoms and risk factors, all structured, curated, and continuously refined by healthcare professionals.

 

In other words: real medical intelligence, not AI guesswork.

 

And here’s why this matters: AI in healthcare does not fail because models are weak. It fails because trust, accuracy, and liability matter. 

 

GLM is designed to operate behind an Enterprise’s firewall, inside regulated environments, with physician oversight, and with explainability and auditability.

 

This is one reason why Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) can deploy AI where many others cannot.

One AI Brain. Endless Applications.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) doesn’t sell “features.”


It deploys solutions.

 

Using the same GLM core, the platform is designed to power an AI Nurse (voice and text) for patient intake and triage, Clinbot for real-time clinical decision support, AI-powered patient charting, EMR integration, kiosks and point-of-care interfaces, remote consultations, and follow-up automation.

 

This matters because: Platforms win. Point solutions lose.

 

Each new deployment strengthens the system.

 

Each new user feeds intelligence.

 

Each new payer integration deepens the moat.

 

Real Traction. Real Scale. Real Patients.

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) already operates at scale with over 700,000 patients served, more than 300 physicians onboarded, active operations across 4 Canadian provinces, live deployment in 3 U.S. states, and functioning as a “Shopify for physicians” where doctors can launch, operate, and scale digital care without rebuilding their practice from scratch.

 

That’s not hype. That’s execution!

The U.S. Healthcare Market: Where Most Companies Die

The United States healthcare market is where ambition goes to die.

 

Why?

 

Because innovation is easy. Reimbursement is not.

 

Most AI healthcare startups collapse when they hit the payer wall of insurance contracts, compliance hurdles, credentialing timelines, regulatory approvals, and multi-payer complexity.12 

 

This is the bottleneck that separates demos from businesses.

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) didn’t ignore this. It leaned into it.

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) has spent years building payer relationships, not months. 

 

The result is access to over 13 million covered lives,13 multi-payer exposure across Medicare Advantage, Commercial, and Medicaid, contracts that take 2.5+ years for competitors to replicate, and a barrier competitors underestimate until it’s too late.

 

The company is currently in-network with major payers including Medicaid in multiple states, Medi-Cal in California, Medicare, Aetna, California Partnership for Health, Emblem Health, Humana, Anthem, United Healthcare, New York State health plans, and Maryland state programs.

 

Once embedded in payer systems, platforms don’t typically get swapped out. They are expanded. 

 

This is the same dynamic that built Epic Systems, Cerner, and major EMR vendors. 

 

Except now, the intelligence layer is AI.

Revenue That Actually Makes Sense

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is already generating revenues across multiple channels with a planned path to profitability.

 

Based on the Q3 2025 financials, its digital health platform and marketplace channel generates $1.66M annualized (ARR) from US and Canadian physicians booking virtual appointments, earning an average 17% fee per Canadian appointment and US$18 flat fee per US appointment.

 

The Partnerships channel contributes $279K annualized (ARR) from pharmacies, allied health partners, and independent provider associations who pay a $250 setup fee and $250 per month for ongoing support, with device-enabled stations available for $3,000. 

 

These IPAs send patients directly to the platform, significantly lowering customer acquisition costs.

 

Platform fees add another $105K annualized(ARR) from monthly subscriptions paid by physicians on the platform, ranging from $25 to $75 per month depending on specialty and geographic location.

 

As of December 1, 2025, annual recurring revenue has reached approximately $2.05M. 

 

Q3 2025 revenue came in at $0.5 million with an impressive 88% gross margin, demonstrating improving margins and expanding use cases.

 

This is not pre-revenue speculation.

 

This is early infrastructure monetization.
And here’s the key: Healthcare platforms don’t explode overnight.
They compound quietly, then dominate.

Proven Results Across Two Countries

CANADA: 700,000+ Patients and Counting

From family medicine to emergency care, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is improving access across the country.

 

The platform has served over 700,000 patients with more than 300 physicians operating in 4 provinces including Alberta, British Columbia, Ontario, and Saskatchewan.

 

Perhaps most impressively, 97% of patients are managed virtually without referral to in-person care, based on a sample of 12,000 patients over a three-month period.

United States: Multi-State Expansion

New York State:

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is building out its presence in New York State, a jurisdiction with a market size of approximately 8.2 million people on Medicare and Medicaid, 9.2 million covered by employer and commercial plans, and approximately 3.5 million members of in-network insurance plans.14

 

Funded through a 5-year, $1M grant from the CVS Health® Foundation, the Company is partnering with EngageWell in a program designed to support older adults in maintaining their health and independence. This initiative is expected to connect to over 700 patients to primary, urgent, and mental health care by Q2 2026.

California:

In California, the single largest healthcare market in the U.S., Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) AI is equally building out its presence where there are approximately 16.4 million Medicare and Medicaid covered lives, 14 million employer and commercial covered lives, and approximately 5 million members of in-network insurance plans.15

 

To date, the platform has treated over 6,000 patients in the state.

Why This is Not "Just Another AI Health Company"

Compare Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) to other names investors throw around.

 

Health Navigator was acquired by Amazon in 2019 for Amazon Care as triage technology for integration.16

 

Ada has a market cap over $600M as a symptom assessment app with 13 million users and 32 million assessments that works with large organizations.17

 

Hippocratic AI reached a $3.5B private market valuation in November 2025 following its $126M Series C funding round, offering safety-focused generative AI agents specifically for healthcare.18

 

Infermedica provides an AI-powered platform for clinical decision support with a strong technical-medical team focused on enterprise diagnostic tools.19

 

OpenEvidence secured a $250 million Series D funding round in January 2026 that doubled its valuation to approximately $12 billion, reflecting strong investor confidence in its AI-powered medical research synthesis platform used by clinicians.20

 

And SoundHound AI, with an approximately $4.07 billion market cap as of January 28, 2026, is a conversational AI leader just entering healthcare with an estimated 15-25% of revenue from the sector.21

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) focuses on designing platforms impacting the end-to-end workflow, payer access, physician adoption, regulatory survivability, and infrastructure depth. This is the difference between a feature and a platform.

 

And platforms are where generational value is built.

Physician Network Scaling Rapidly

While most competitors struggle to recruit physicians, Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is growing its network through fellow physician referrals.

 

The company has recruited from elite institutions including Harvard, Stanford, Johns Hopkins, UCSF, and Geisinger.

 

According to company disclosures, Rocket Doctor AI has begun to see early momentum in physician onboarding, with a growing pipeline of qualified physician leads across Medicare Advantage, commercial, and Medicaid payer programs as additional plans go live.

 

Full payer activation is expected to trigger step-change growth of their network.

 

The company has set up an infrastructure and relationships to rapidly recruit more physicians as demand rises, a critical advantage most competitors cannot easily replicate.

The Doctor-led Advantage

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is not just built by software engineers pretending to understand medicine.

 

It’s designed by practicing physicians who live on the front lines every day and work “hand in glove” with their technology teams.

 

The experienced leadership team includes physicians with backgrounds from Johns Hopkins University, University of Toronto, University of California San Francisco, University of Calgary, University of Alberta, Harvard, Stanford, Berkeley, and Geisinger, as well as deep expertise across clinical decision support, chronic disease management, virtual care, family medicine, emergency medicine, primary care, psychiatry, addiction medicine, pediatrics, quality improvement, and provider success.

LEADERSHIP TEAM

Dr. Essam Hamza, MD, CCFP

CEO, Rocket Doctor AI Inc.
  • Experienced physician-entrepreneur: Primary care physician with 25+ years of medical experience and a proven track record building and scaling healthcare companies, including founding CloudMD Inc.
  • Proven scale operator: As a leader at CloudMD (2019–2022), helped drive growth from ~$4M in annual revenue and a small team to $100M+ in annual revenue with hundreds of employees and customers across North America.
  • Healthcare innovator & CEO: Early adopter of digital primary care and clinic automation in Canada; appointed CEO of Treatment.com AI in October 2023.

Dr. William Cherniak, MD, MPH, CCFP(EM) 

Founder & CEO, Rocket Doctor Inc.
  • Emergency medicine & public health expert: Practicing emergency physician, University of Calgary Medical School graduate with an MPH from the Johns Hopkins Bloomberg School of Public Health, where he was a Sommer Scholar and NIH/NCI Global Cancer Control Fellow.
  • Global health leadership: Co-Founder and Board Chair of Bridge to Health Medical and Dental, a Canadian charity and U.S. 501(c)(3) that has trained 800+ healthcare workers and delivered free care to 50,000+ patients across East Africa, the Middle East, and Latin America.
  • Academic & clinical educator: Faculty appointments at the University of Toronto (Emergency Medicine), Johns Hopkins Bloomberg School of Public Health, and prior teaching roles at USC Keck School of Medicine and Northwestern University.

Dr. Kevin Peterson, MD, MPH, FRCS(Ed), FAAFP

Co-Founder & CMO, Rocket Doctor AI
  • National healthcare and research leader: Primary care physician specializing in chronic disease management, diabetes, bioinformatics, and clinical trials; former Vice President of Primary Care at the American Diabetes Association and Professor Emeritus at the University of Minnesota Medical School.
  • Proven NIH & AHRQ research authority: Principal Investigator on numerous NIH-funded studies and former National Director of the AHRQ PBRN Resource Center, supporting research across 17,000+ primary care practices and helping build a national electronic primary care research infrastructure.
  • Medical AI innovator: Co-Founder of Treatment.com, with 25+ years translating research into community clinical practice; Fellow of the American Academy of Family Physicians and the Royal College of Surgeons (Edinburgh), and developer of multiple medical technologies.

Richard Atkins 

COO, Rocket Doctor AI
  • Seasoned commercial and M&A leader: 30+ years of experience in international sales, strategic partnerships, executive management, and M&A, including multiple multi-million-dollar transactions with leading health-tech and software companies.
  • Deep healthcare and technology expertise: Background spanning enterprise software and infrastructure (cloud, data centers, CRM, analytics, omnichannel contact centers), with the past 15 years focused on healthcare across the continuum of care and clinical decision support.
  • Digital health and interoperability specialist: Hands-on experience with telehealth, healthbots, symptom checkers, teletriage services, managed PACS/RIS and LIMS, and EMR/billing systems, including HL7/FHIR interoperability across public and private healthcare systems.

Harry Cherniak 

Co-Founder, COO & Privacy Officer, Rocket Doctor
  • Corporate strategy, legal, and M&A expert: Holds an HBA (Ivey Business School), MSc (London School of Economics), and JD (University of Toronto); former corporate lawyer at Torys LLP with deep experience in complex M&A and corporate transactions.
  • Blue-chip transaction experience: Advised on multi-billion-dollar deals involving leading institutions including Scotiabank, Canadian Tire, Sun Life, Manulife, Rogers Communications, Bell Canada, and private equity firms across acquisitions, financings, and shareholder arrangements.
  • Public policy and international perspective: Professional experience in London working with Jon Trickett MP, providing exposure to UK public policy and business regulation at the national level.

Why This Opportunity Still Exists

The absence of hype often masks where real demand exists.

There is a clear disconnect between underlying demand and how the market is currently valuing access to this opportunity.

 

But, because Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) trades quietly, it still flies under the radar.

 

Retail investors haven’t connected the dots yet on AI healthcare infrastructure, payer moats, physician distribution, real ARR, and scalable intelligence.

 

This is the same blind spot investors had with early EMR vendors, early fintech rails, and early cloud infrastructure.

 

By the time Wall Street “gets it,” the asymmetry is gone.

The Quiet Accumulation Phase

Every major platform story follows the same arc. Build quietly. Solve hard problems. Earn trust. Embed deeply. Scale invisibly. Re-rate violently.

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is somewhere between steps 3 (earn trust) and 4 (embed deeply), it has now entered its commercialization phase.

 

That’s the window where risk is still manageable and upside is asymmetric.

 

Healthcare is the largest, slowest, and most expensive system on Earth. 

 

It will not be fixed by slogans. It will not be fixed by governments. And It will not be fixed by apps. 

 

It will be fixed by trusted infrastructure.

 

And infrastructure always rewards those who understand it early.

 

Rocket Doctor AI Inc. (CSE: AIDR | OTC: AIRDF | WKN: A41FSK) is not selling the future.

 

It’s quietly building it.

Final Thoughts

If you’re looking for noise, this isn’t it. If you’re looking for hype, this isn’t it.

But if you’re looking for early exposure to AI healthcare infrastructure before the crowd arrives, this is exactly where you should be looking.

These favorable entry points have a limited duration.

Eventually, market participants recognize the opportunity. Institutional investors take positions. 

Research analysts release coverage reports. Media sentiment shifts positively. Individual investors enter the market.

At that stage, the chance to establish early positions has passed.

Sophisticated investors don’t wait for mainstream recognition. 

They take positions before widespread market awareness develops.

Situations like this don’t remain under the radar indefinitely.

Investors are beginning to take a closer look at Rocket Doctor AI today.

The choice is yours!

Quick Links To Preferred Brokerages

Stock Information

Rocket Doctor AI Inc. 

CSE: AIDR

OTC : AIRDF

Investor Presentation

Stay up to date and subscribe to our investor newsletter.

Disclaimers

PAID ADVERTISEMENT This communication is a paid advertisement and is not a recommendation to buy or sell securities. Danayi Capital Corp. (collectively with its owners, managers, employees, and assigns “Danayi Capital Corp.”) has been paid $125,000 United States dollars (US$) by Rocket Doctor AI Inc. (plus applicable taxes) for an ongoing marketing campaign including this article among other things. This compensation is a major conflict with our ability to be unbiased. This communication is for entertainment purposes only. Never invest purely based on our communication. Danayi Capital Corp. owns and operates the website www.wallstreetlogic.com and its associated landing pages.

 

SHARE OWNERSHIP The owner of Danayi Capital Corp. may be buying and selling shares of this issuer for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.

 

NOT AN INVESTMENT ADVISOR Danayi Capital Corp. and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation.

 

ALWAYS DO YOUR OWN RESEARCH Always consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.

 

RISK OF INVESTING Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don’t trade with money you can’t afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.

 

Forward-Looking Statements and Legal Disclaimers – Please Read Carefully.

This landing page contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to, among other things, expectations regarding the adoption, scalability, commercialization, and future performance of artificial intelligence–enabled healthcare platforms, revenue growth, payer integration, physician adoption, regulatory outcomes, and the Company’s business strategy and market opportunity.


Forward-looking statements are subject to a variety of known and unknown risks, uncertainties, and other factors that could cause actual results, performance, or events to differ materially from those expressed or implied by such statements. Risks and uncertainties that could cause actual outcomes to differ include, but are not limited to: the risk that demand for digital or AI-enabled healthcare solutions does not increase as anticipated; that patients, physicians, payers, or healthcare systems may be slow to adopt or may reject AI-powered medical platforms; that regulatory, compliance, reimbursement, or licensing requirements may change or prove more restrictive than expected; that payer relationships, insurance coverage, or reimbursement rates may be delayed, reduced, terminated, or not expanded as anticipated; that technological developments or competing solutions may reduce the relevance or effectiveness of the Company’s platform; that artificial intelligence tools may fail to perform as expected or may encounter accuracy, safety, liability, or explainability challenges; that the Company may be unable to successfully integrate with electronic medical records, healthcare systems, or payer infrastructure; that operational, data security, privacy, or cybersecurity risks may arise; that physician recruitment, retention, or utilization may not scale as planned; that partnerships or grant-funded initiatives may not generate expected outcomes; that revenue growth, margins, or profitability may not be achieved; that the Rocket Doctor AI Inc. may be unable to raise sufficient capital to execute its business plans; or that management may be unable to successfully implement or scale the Company’s strategy.


Forward-looking statements are based on management’s current expectations, assumptions, and beliefs as of the date hereof and are subject to change. Readers are cautioned not to place undue reliance on forward-looking information. Danayi Capital Corp. undertakes no obligation to update or revise any forward-looking statements or information to reflect new events, circumstances, or changes in expectations, except as required by applicable law.

Non-GAAP Financial Metrics
Non-GAAP measure. This article contains financial measures not prepared in accordance with generally accepted accounting principles (referred to as Non-GAAP). Specifically, annual recurring revenue (“ARR”) should not be construed as alternatives to net income/loss determined in accordance with IFRS. ARR does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers. The Company defines ARR as “the total value over the preceding twelve months of all recognized revenues in accordance with IFRS, plus all otherwise contracted for revenue commitments from customers, stemming from or related to all ongoing revenue sources.”. The most directly comparable GAAP financial measure to ARR is revenue. Rocket Doctor AI Inc. believes that ARR is a meaningful financial metric for investors as it adjusts revenue to reflect amounts which Rocket Doctor anticipates recognizing as revenue from contracted agreements and provides a year-over-year comparison to assist in measuring revenue growth.

Additional Disclaimer
This publication is part of an advertising campaign for the company under discussion and is aimed at experienced and speculatively oriented investors. This review of Rocket Doctor AI Inc. should not be construed as an independent financial analysis or even investment advice, as there are significant conflicts of interest that may affect the objectivity of the preparers (see the following section “Disclosure of Interests and Conflicts of Interest and Conflict of Interest Prevention Policies”).

Legal Notices
Type of information: Marketing communication
Publisher: Danayi Capital Corp., a company incorporated in British Columbia, Canada.
Date of first creation: on or about February 1, 2025
Time of first creation: on or about 05:30AM PST
Creator of the marketing communication: Danayi Capital Corp.
Coordination with the issuer: Yes
Addressees: Danayi Capital Corp. makes the securities analysis available to all interested investment service providers and private investors at the same time.
Sources: Information sources of Danayi Capital Corp. are information of the issuer, domestic and foreign business press, information services, news agencies (e.g. Reuters, Bloomberg, Infront, etc.), analyses and publications on the Internet.
Scale of care: Valuations and investment judgments derived from them are prepared with the greatest possible care and taking into account all factors that are recognizably relevant at the respective time.

Disclosure of interests and conflicts of interest, as well as conflict of interest prevention policies

Danayi Capital Corp. receives a fixed fee from Rocket Doctor AI Inc. for the distribution of the marketing communication.
Because other research houses and stock market letters can also discuss the value, there may be a symmetrical generation of information and opinion in the current recommendation period.  Of course, it is important to note that Rocket Doctor AI Inc. is listed in the highest conceivable risk class for stocks. The company may not yet have any sales and is at an early-stage level, which is both attractive and risky. The company’s financial situation is still loss-making, which significantly increases the risks. Capital increases that become necessary could also lead to dilution in the short term, which could be to the detriment of investors. If the company does not succeed in tapping into further sources of finance in the next few years, insolvency and delisting could even be threatened.

Declaration of release from liability and risk of total loss of invested capital

We would like to point out that equity investments are always associated with risk. Every transaction with warrants, leverage certificates or other financial products is even fraught with extremely high risks. Due to political, economic or other changes, there can be considerable price losses, in the worst case a total loss of the capital employed. With derivative products, the probability of extreme losses is at least as high as with small-cap shares, whereby the large domestic and foreign stocks can also suffer severe price losses up to a total loss. You should seek further advice before making any investment decision (e.g. from your bank or an advisor you trust).
Although the evaluations and statements contained in the analyses and market assessments of stock metrics have been prepared with reasonable care, we do not accept any responsibility or liability for errors, omissions or misstatements. This also applies to all representations, figures and assessments expressed by our interlocutors in the interviews. The entire risk arising from the use or performance of the Service and Materials remains with you, the reader. To the maximum extent permitted by applicable law, Danayi Capital Corp. shall not be liable for any special, incidental, indirect, or consequential damages (including, but not limited to, lost profits, business interruption, loss of business information, or any other pecuniary loss) arising out of the use of, or inability to use, the Service and Materials.
All statements in this report regarding Rocket Doctor AI Inc., other than statements of historical fact, should be construed as forward-looking statements that may not materially prove to be true due to significant uncertainties. The author’s statements are subject to uncertainties that should not be underestimated. There is no certainty or guarantee that the forecasts made will actually come true. Therefore, readers should not rely on the statements of stock metrics and should buy or sell securities only based on reading the report.


Users who make investment decisions or carry out transactions on the basis of the information displayed or ordered for Danayi Capital Corp. act entirely at their own risk.


The reader hereby assures that he uses all materials and content at his own risk and that Danayi Capital Corp. assumes no liability.
Danayi Capital Corp. reserves the right to modify, improve, expand or remove the content and materials without notice. Danayi Capital Corp. excludes any warranty for service and materials. The Service and Materials and the related documentation are provided to you “as is” without warranty of any kind, either express or implied. Including, but not limited to, implied warranties of merchantability, fitness for a particular purpose, or non-infringement.


The recommendations, interviews and company presentations published on this website fulfil advertising purposes without exception and are commissioned and paid for by third parties or the respective companies. For this reason, the analyses are not independent research studies.


There is no guarantee that the forecasts of the Company, the analyst or other experts and the management will actually come true. The performance of Rocket Doctor AI Inc. shares is therefore uncertain. As with any so-called microcap, there is also a risk of total loss.


The investor should follow the news closely and have the technical requirements for trading in penny stocks. The narrowness of the market, which is typical of the segment, ensures high volatility. Inexperienced investors and LOW-RISK investors are generally advised not to invest in shares of Rocket Doctor AI Inc. This analysis is aimed exclusively at experienced professional traders.


The author does not guarantee the completeness, timeliness or quality of the information provided. Liability claims against the author are excluded, as far as a negligent act is concerned. The author reserves the right to revise, supplement or delete parts of his statements.


Impressum (Required Information According to § 5 TMG)
Danayi Capital Corp.
Commercial Register:
550 – 800 West Pender Street, Vancouver, British Columbia, V6C 2V6, Canada
Represented by:
Mehran Bagherzadeh
Contact:
Phone: 6047672983
Email: Mehran@danayi.co

References

No Result
View All Result

© 2024 Wallstreetlogic.com - All rights reserved.